Literature DB >> 25150423

αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer.

Anna Sophie Berghoff1, Astrid Kerstin Kovanda, Thomas Melchardt, Rupert Bartsch, Johannes A Hainfellner, Bence Sipos, Jens Schittenhelm, Christoph C Zielinski, Georg Widhalm, Karin Dieckmann, Michael Weller, Simon L Goodman, Peter Birner, Matthias Preusser.   

Abstract

Integrins are transmembranous adhesion molecules postulated to be involved in the brain metastatic cascade. We investigated the correlation of alpha v beta 3 (αvβ3), alpha v beta 5 (αvβ5) and alpha v beta 6 (αvβ6) integrin isoform expression with clinical characteristics including survival times in lung cancer patients with brain metastases (BM). All BM from lung cancer operated at our institution between 1990 and 2011, were identified; where available, primary tumors were retrieved as well. Immunohistochemical analysis for αvβ3, αvβ5 and αvβ6 integrin subunits was performed and correlated with Ki67 and hypoxia-inducible factor (HIF)-1α indexes. Clinical data including survival data were obtained by chart review. 191 BM specimens of 191 patients with histologically confirmed lung cancer (172 non-small cell lung cancer and 19 small cell lung cancer) were included. In 18 patients matched primary tumor samples were available. αvβ6 expression was commonly found on BM tumor cells (103/191; 53.9 %) and showed a significant association with low Ki67 proliferation indices (46 vs. 36 %, p = 0.001, Mann-Whitney U test) and favorable survival times (p = 0.020; log rank test) in patients with non-squamous NSCLC BM. αvβ5 expression was highly expressed on vascular structures (167/191; 87.4 %) and tumor stroma in BM (151/191; 79.1 %) and associated with high HIF-1α indices (60 vs. 90, p = 0.007, Mann-Whitney U test). αvβ3 expression was more frequently found on vascular structures in BM than in primary tumors (68.1 vs. 5.6 %; p = 0.645; Chi square test) and its expression in BM tumor cells correlated with low Ki67 indices (41 vs. 28 %; p = 0.046, Mann-Whitney U test). Expression of αv integrin subunits seem to be of pathobiological and clinical relevance in patients with NSCLC BM. Further investigations of their involvement in the brain metastatic cascade and their role as biomarkers are warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25150423     DOI: 10.1007/s10585-014-9675-0

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  51 in total

1.  Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study.

Authors:  Tobias Bäuerle; Dorde Komljenovic; Maximilian Merz; Martin R Berger; Simon L Goodman; Wolfhard Semmler
Journal:  Int J Cancer       Date:  2011-05-15       Impact factor: 7.396

2.  Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors.

Authors:  C L Gladson
Journal:  J Neuropathol Exp Neurol       Date:  1996-11       Impact factor: 3.685

3.  Expression of integrin beta 6 enhances invasive behavior in oral squamous cell carcinoma.

Authors:  Daniel M Ramos; Maria But; Joseph Regezi; Brian L Schmidt; Amha Atakilit; Dongmin Dang; Duncan Ellis; Richard Jordan; Xiaowu Li
Journal:  Matrix Biol       Date:  2002-04       Impact factor: 11.583

4.  Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis.

Authors:  T Kageshita; C V Hamby; S Hirai; T Kimura; T Ono; S Ferrone
Journal:  Cancer Immunol Immunother       Date:  2000-08       Impact factor: 6.968

5.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

6.  Longitudinal expression analysis of αv integrins in human gliomas reveals upregulation of integrin αvβ3 as a negative prognostic factor.

Authors:  Jens Schittenhelm; Esther I Schwab; Jan Sperveslage; Marcos Tatagiba; Richard Meyermann; Falko Fend; Simon L Goodman; Bence Sipos
Journal:  J Neuropathol Exp Neurol       Date:  2013-03       Impact factor: 3.685

7.  Alpha(v)beta(6) integrin-A marker for the malignant potential of epithelial ovarian cancer.

Authors:  Nuzhat Ahmed; Clyde Riley; Gregory E Rice; Michael A Quinn; Mark S Baker
Journal:  J Histochem Cytochem       Date:  2002-10       Impact factor: 2.479

8.  Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain.

Authors:  Mihaela Lorger; Joseph S Krueger; Melissa O'Neal; Karin Staflin; Brunhilde Felding-Habermann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-16       Impact factor: 11.205

9.  A mosaic mouse model of astrocytoma identifies alphavbeta8 integrin as a negative regulator of tumor angiogenesis.

Authors:  J H Tchaicha; A K Mobley; M G Hossain; K D Aldape; J H McCarty
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

10.  Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Authors:  Ludmila Prudkin; Diane D Liu; Natalie C Ozburn; Menghong Sun; Carmen Behrens; Ximing Tang; Kathlynn C Brown; B Nebiyou Bekele; Cesar Moran; Ignacio I Wistuba
Journal:  Mod Pathol       Date:  2009-03-06       Impact factor: 7.842

View more
  23 in total

1.  Genetic variants associated with colorectal brain metastases susceptibility and survival.

Authors:  S Stremitzer; A S Berghoff; N B Volz; W Zhang; D Yang; S Stintzing; Y Ning; Y Sunakawa; S Yamauchi; A Sebio; S Matsusaka; S Okazaki; D Hanna; A Parekh; A Mendez; M D Berger; R El-Khoueiry; P Birner; M Preusser; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2015-12-22       Impact factor: 3.550

2.  Preclinical Development and First-in-Human Imaging of the Integrin αvβ6 with [18F]αvβ6-Binding Peptide in Metastatic Carcinoma.

Authors:  Sven H Hausner; Richard J Bold; Lina Y Cheuy; Helen K Chew; Megan E Daly; Ryan A Davis; Cameron C Foster; Edward J Kim; Julie L Sutcliffe
Journal:  Clin Cancer Res       Date:  2018-11-06       Impact factor: 12.531

Review 3.  Unsanctifying the sanctuary: challenges and opportunities with brain metastases.

Authors:  Shannon Puhalla; William Elmquist; David Freyer; Lawrence Kleinberg; Chris Adkins; Paul Lockman; John McGregor; Leslie Muldoon; Gary Nesbit; David Peereboom; Quentin Smith; Sara Walker; Edward Neuwelt
Journal:  Neuro Oncol       Date:  2015-05       Impact factor: 12.300

4.  PET/CT Imaging of NSCLC with a αvβ6 Integrin-Targeting Peptide.

Authors:  Paul Flechsig; Thomas Lindner; Anastasia Loktev; Saskia Roesch; Walter Mier; Max Sauter; Michael Meister; Christel Herold-Mende; Uwe Haberkorn; Annette Altmann
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

5.  T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways.

Authors:  Yukinori Endo; Yi Shen; Lamis Abou Youssef; Nishant Mohan; Wen Jin Wu
Journal:  MAbs       Date:  2018-09-11       Impact factor: 5.857

Review 6.  Integrin ανβ6 Protein Expression and Prognosis in Solid Tumors: A Meta-Analysis.

Authors:  Alexandra Desnoyers; Carlos González; Pedro Pérez-Segura; Atanasio Pandiella; Eitan Amir; Alberto Ocaña
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

7.  Positron emission tomography of cerebral angiogenesis and TSPO expression in a mouse model of chronic hypoxia.

Authors:  Iwao Kanno; Chie Seki; Hiroyuki Takuwa; Zhao-Hui Jin; Didier Boturyn; Pascal Dumy; Takako Furukawa; Tsuneo Saga; Hiroshi Ito; Kazuto Masamoto
Journal:  J Cereb Blood Flow Metab       Date:  2017-01-27       Impact factor: 6.200

8.  Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications.

Authors:  Mehdi Azizi; Hassan Dianat-Moghadam; Roya Salehi; Masoud Farshbaf; Disha Iyengar; Samaresh Sau; Arun K Iyer; Hadi Valizadeh; Mohammad Mehrmohammadi; Michael R Hamblin
Journal:  Adv Funct Mater       Date:  2020-03-03       Impact factor: 18.808

9.  Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.

Authors:  P-F Zhang; K-S Li; Y-H Shen; P-T Gao; Z-R Dong; J-B Cai; C Zhang; X-Y Huang; M-X Tian; Z-Q Hu; D-M Gao; J Fan; A-W Ke; G-M Shi
Journal:  Cell Death Dis       Date:  2016-04-21       Impact factor: 8.469

10.  Multimodal evaluation of hypoxia in brain metastases of lung cancer and interest of hypoxia image-guided radiotherapy.

Authors:  Samuel Valable; Jade Fantin; Aurélien Corroyer-Dulmont; Laurent Chatre; Jérôme Toutain; Sylvain Teulier; Céline Bazille; Elise Letissier; Jérôme Levallet; Didier Divoux; Méziane Ibazizène; Stéphane Guillouet; Cécile Perrio; Louisa Barré; Sébastien Serres; Nicola R Sibson; Françoise Chapon; Guénaëlle Levallet; Myriam Bernaudin
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.